GERMAN SPRING CONFERENCE - EQUITY FORUM - DR STEFAN M. MANTH CHIEF EXECUTIVE OFFICER FRANKFURT, 15 MAY 2019
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
GERMAN SPRING CONFERENCE – EQUITY FORUM DR STEFAN M. MANTH CHIEF EXECUTIVE OFFICER FRANKFURT, 15 MAY 2019 1
MOLOGEN AT A GLANCE
• Based in Berlin, Germany; founded 1998
• Publicly quoted on Frankfurt Stock Exchange Structure of lefitolimod
Prime Standard (MGNK); ISIN: DE000A2LQ900
• Approx. 50 highly qualified employees
• Pioneer focused on TLR9 agonists:
• Lead compound: lefitolimod Structure of EnanDIM®
• Next generation technology: EnanDIM®
• Targeting highly attractive markets: Market for
cancer immunotherapies expected to exceed
US$100 billion by 2024*
• Network with renowned scientific institutions and experts
• Strategic partnership with ONCOLOGIE Inc.
2 Notes: *According to Market and Research (https://www.researchandmarkets.com/reports/4606290/global-cancer-immunotherapies-
market-to-2024)MOLOGEN SUMMARY HIGHLIGHTS
Advanced immunotherapy player
• Lefitolimod: Advanced clinical development stage
• Phase III study in mCRC: top line data available in summer 2019
• Ongoing combination trials in oncology and HIV
• Safe and well tolerated lead compound (over 460 patients closed to date)
• EnanDIM®: Clinical candidate phase I-ready by end of 2019
License deal with ONCOLOGIE Inc., U.S., in Feb 2018
• Development and commercialization for Asian markets (China, Hong Kong, Macao,
Taiwan and Singapore) as well as a global development agreement
Recent capital measures:
• Convertible bond fully placed in Jan 2019 with gross proceeds of around €2.7 million
• Capital increase finalized in Mar 2019 with gross proceeds of around €4.2 million
3 Notes: mCRC metastatic Colorectal CancerPIPELINE: IMMUNOTHERAPIES WITH WIDE RANGE OF
POTENTIAL INDICATIONS
STUDY Preclinical PHASE I PHASE II PHASE III
LEFITOLIMOD
mCRC
IMPALA
Monotherapy
SCLC (extensive stage)
IMPULSE
Monotherapy
Advanced solid tumors1
IO-combination therapy
HIV2
TEACH
Monotherapy3
HIV2
TITAN
Combination therapy4
Solid tumors
IO-combination therapy
EnanDIM®
EnanDIM®
Candidates: Oncology
EnanDIM®
Candidates: HIV
MGN1601
Renal cancer ASET
1Collaboration with MD Anderson Center, Texas, US 2Collboration with University Hospital Aarhus, Denmark
Oncology
4 3HIV patients under retroviral therapy (ART) 4With broadly neutralizing antibodies
Infectious diseases IO=Immuno-oncology / mCRC = metastatic Colorectal Cancer / SCLC = Small Cell Lung CancerPRINCIPLE OF ANTI CANCER IMMUNOTHERAPY
Traditional Chemotherapy Immunotherapy Combination Therapy Potential
• Fast effect in many patients • Delayed onset of effect • Combination treatments aim
• Effect not lasting to combat cancer through
• Sustainable disease control various synergistic MoA*
in a subgroup of patients
• Lefitolimod uniquely
positioned as potential
“combination partner of
choice”
Patients alive in %
Immunotherapy
Combination therapies
Control
group
time
• Combination therapies are expected to increase the efficacy of the treatment by leveraging
synergistic effects and to optimally activate the body’s immune system
5 Source: "Immuno-oncology: The new weapon in the war against cancer”, Alistair Campbell; Berenberg Equity Highlights,
February 2014
Legend: OS overall survival; *MoA Mode-of-ActionLICENSE AGREEMENT WITH ONCOLOGIE INC.
• Feb 2018: MOLOGEN signed a license and global
co-development agreement with ONCOLOGIE for lead
compound lefitolimod:
• License for China, Hong Kong, Macao, Taiwan, and Singapore
• Global Co-development with a focus on combination therapies
• ONCOLOGIE Inc. (www.oncologie.international):
• Objective to develop personalized medicine in immuno-oncology
• Dedicated to biomarker-driven development of large and small molecules
• Strong leadership of industry veterans
• Headquartered in Boston, U.S., with operations in Boston and Shanghai
6KEY FINANCIALS Q1 2019 & FY 2018 (IFRS)
Q1 Q1 FY FY
In € m ∆* ∆*
2019 2018 2018 2017
R&D expenses 2.2 2.9 25% 10.3 14.0 26%
EBIT -3.6 -0.7 -405% -11.3 -18.7 39%
Cash flows from operating activities -4.3 -4.6 7% -13.7 -19.1 28%
Cash flows from financing activities 2.7 6.3 -57% 15.2 5.1 198%
Monthly cash burn 1.3 1.6 19% 1.1 1.7 35%
31 Mar 31 Dec 31 Dec 31 Dec
In € m ∆* ∆*
2019 2018 2018 2017
Total assets 7.9 9.4 -15% 9.4 8.1 16%
Cash & cash equivalents 6.5 8.0 -19% 8.0 6.5 23%
7 * Economic view / minus = neg. impact on business, plus = pos. impactFINANCING – 2018 UP TO DATE
In €m
Initial payment from ONCOLOGIE (licensing agreement Greater China 04/18) 3.0
Convertible bonds ONCOLOGIE (5 years, 0% interest rate) 2.0
Share Subscription Facility with GCF, US: up to 10% of outstanding MGN shares 1.0
Financing Agreement with EHGO, LUX 1.0
Capital increase with subscription rights – April 2018 ~ 5.0
Capital increase with subscription rights – September 2018 ~ 8.2
Convertible bonds 2019/2027 (8 years, 6% interest rate) ~ 2.7
Capital increase with subscription rights – April 2019 ~ 4.2
Total gross proceeds ~ 27.1
• Cash reach presumably until end of 2019 - based on current cash position
8 Legend: EHGO European High Growth Opportunities | GCF Global Corporate FinanceOUTLOOK 2019
• Focus on near-to-market lead compound lefitolimod and successor molecules EnanDIM®
• Q2: Start TITAN study
• Q3: IMPALA top line data expected
• Q4: EnanDIM® phase I-readiness
• Ongoing partnering discussions
• Ensure further financing beyond end of 2019
• Additional combination trials in oncology
• Outcome of IMPALA study has significant impact on further development of the Company
9FINANCIAL CALENDAR 2019 AND CONTACT DETAILS
30 April 2019
Full Year Report 2017
9 May 2019
Quarterly Statement as of 31 March 2019
14 August 2019
Half-Yearly Financial Report as of 30 June 2019
22 August 2019
Annual General Meeting Claudia Nickolaus
Head of Investor Relations &
7 November 2019
Corporate Communications
Quarterly Statement as of 30 September 2019
Phone: +49-30-841788-37
Fax: +49-30-841788-50
investor@mologen.com
www.mologen.com
10 MOLOGEN®, MIDGE®, dSLIM®, and EnanDIM® are registered trademarks of the MOLOGEN AGDISCLAIMER This presentation does not constitute an offer to buy shares or other securities of MOLOGEN AG and does not replace the prospectus. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. There will be no public offer of the securities in the United States. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States. Note about risk for future predictions Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this presentation regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward- looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication. 11
GERMAN SPRING CONFERENCE – EQUITY FORUM DR STEFAN M. MANTH CHIEF EXECUTIVE OFFICER FRANKFURT, 15 MAY 2019 12
You can also read
